Aware Super Pty Ltd as trustee of Aware Super Buys New Shares in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Aware Super Pty Ltd has purchased 354,910 shares of BioMarin Pharmaceutical Inc. for approximately $19.5 million, gaining a 0.19% ownership stake in the company.
• Analysts have mixed ratings for BioMarin, with 13 recommending a "Buy" rating and one issuing a "Sell," resulting in an average price target of $93.26.
• BioMarin’s stock has been characterized by a market capitalization of $10.19 billion and a P/E ratio of 15.75, amidst a one-year price range between $51.56 and $73.51.

Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 354,910 shares of the biotechnology company's stock, valued at approximately $19,509,000. Aware Super Pty Ltd as trustee of Aware Super owned 0.19% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Rise Advisors LLC acquired a new position in BioMarin Pharmaceutical during the first quarter valued at $30,000. Farther Finance Advisors LLC boosted its position in shares of BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 211 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $25,000. Brooklyn Investment Group lifted its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 540 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of BioMarin Pharmaceutical in the 1st quarter valued at approximately $71,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMRN has been the subject of a number of analyst reports. Guggenheim boosted their price objective on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Weiss Ratings restated a "sell (d+)" rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 8th. Wall Street Zen downgraded BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Wedbush reissued an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. Finally, Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Thirteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $93.26.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $53.09 on Thursday. The company has a market cap of $10.19 billion, a P/E ratio of 15.75, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a one year low of $51.56 and a one year high of $73.51. The business has a fifty day moving average of $55.87 and a two-hundred day moving average of $57.79. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.